Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation (CAF)
Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation (CAF Trial)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Utah
-
Murray, Utah, United States, 84143
- Intermountain Heart Institute
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female >65 years of age.
- Non-valvular atrial fibrillation documented by electrocardiogram, ambulatory event monitor, or telemetry within 12 months of enrollment.
- Moderate risk of thromboembolism based upon a CHADS score or CHADS2 Vasc score of ≥2.
- Ability to complete a mini-mental status evaluation.
- Ability to independently comprehend and complete a quality of life and dementia questionnaires.
- Ability to provide informed consent for study participation.
- Willing and able to comply with the prescribed follow-up tests and schedule of evaluations.
Exclusion Criteria:
- Inability to take an anticoagulant due to known or perceived bleeding risk.
- Known coagulopathy that may impact the choice, duration, efficacy and safety of anticoagulation therapy.
- Atrial Fibrillation in the setting of valvular heart disease. Valvular heart disease defined as any surgical valve, mitral stenosis, or moderate-severe valvular heart disease.
- Severe renal dysfunction, defined as a creatinine clearance rate <15 mL/min (documented within the last 3 months).
- History of any form of dementia.
- A life expectancy less than 24 months.
- Inability to comply with the follow-up schedule.
- Current participation in a clinical investigation that includes an active pharmacologic treatment arm.
- An upper age limit not to be used if participation inclusion criteria are met.
- Participation in any other clinical trials involving investigational or marketed products within 30 days prior to entry in the study.
- Other conditions that in the opinion of the Principal Investigator(s) may increase risk to the subject and/or compromise the quality of the clinical trial.
- Concurrent pharmacologic treatment that is required to treat a condition long-term in which concurrent use of dabigatran etexilate is contraindicated.
Treatment with any anticoagulant drug for stroke prevention for more than 30 days.
- Aspirin and P2Y12 inhibitors (e.g. clopidogrel (Plavix), or prasugrel (Effient)) are not considered anticoagulant drugs.
- If the subject has received any anticoagulant drug for stroke prevention for less than 30 days, the Principal Investigator(s) or a Co-Investigator will decide whether or not the subject is eligible for this study
- The Principal Investigator(s) determine(s) that the subject is not eligible for participation in this research study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Dabigatran Etexilate
150 mg BID (CrCL > 30 mL/min) or 75 mg BID (CrCL 15-30 mL/min)
|
150 mg BID (CrCL > 30 mL/min) or 75 mg BID (CrCL > 15 to 30 mL/min); Assessment of kidney function every 6 months.
Other Names:
|
|
Active Comparator: Warfarin
Dose-adjusted warfarin (INR: 2.0-3.0)
|
Dose-adjusted (INR 2.0 - 3.0); Standard warfarin follow-up and education based upon system criteria.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With Incident Dementia Determined by a Formal Diagnosis of Dementia by a Neurologist
Time Frame: 24 months
|
Incident dementia will be determined by a formal diagnosis of dementia by a neurologist
|
24 months
|
|
Number of Participants With Moderate Decline in Cognitive Function Based on Results of the Alzheimer's Disease Assessment Scale and the Disability Assessment for Dementia.
Time Frame: 24 months
|
Determined by measuring the change from baseline to study conclusion on the 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog11, with scores ranging from 0 to 70, and higher scores indicating greater impairment) and the Disability Assessment for Dementia (DAD, with scores ranging from 0 to 100, and higher scores indicating less impairment).
An increase in ADAS-cog11 of >30% is considered significant for moderate cognitive decline.
In subjects that score <50% on the DAD, there is a direct correlation with global deterioration scales and scores.
Subjects with a 30% decrease in DAD score or those with a score <50% will be considered to have moderate cognitive decline.
These scores will be aggregated and if a patient meets either one of the cognitive decline definitions they will be deemed positive for cognitive impairment.
|
24 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With Stroke or Transient Ischemic Attack (TIA) or Intracranial Bleed
Time Frame: 24 months
|
24 months
|
|
|
Percent Change From Baseline in Mini-Mental State Examination Scores.
Time Frame: 24 months
|
The Mini-Mental State Examination (MMSE) is commonly used to measure cognitive change over time.
Scores on the MMSE range from 0 to 30.
Any score of 24 or more indicates a normal cognition.
Below this, scores can indicate severe (≤9 points), moderate (10-18 points) or mild (19-23 points) cognitive impairment.
We measured the percent change from baseline scores.
|
24 months
|
|
Changes From Baseline Scores on the Hachinski Ischemic Scale
Time Frame: 24 months
|
The Hachinski Ischemic Scale (HIS) is commonly used clinical tool to differentiate between different types of dementia.
Scores on the HIS range from 0 to 18.
A score of less than 4 suggests primary dementia.
A score of 4-7 is indeterminate.
A score more than 7 suggests vascular dementia.
We measured percentage change from baseline scores on the HIS.
|
24 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Mental Disorders
- Neurocognitive Disorders
- Dementia
- Cognition Disorders
- Pyridines
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Benzimidazoles
- Heterocyclic Compounds, 2-Ring
- Heterocyclic Compounds, Fused-Ring
- Pyrans
- Coumarins
- Benzopyrans
- 4-Hydroxycoumarins
- Dabigatran
- Warfarin
Other Study ID Numbers
Other Study ID Numbers
- 1050164
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.